Robert Malenka Sells 736 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 736 shares of the stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $18.15, for a total transaction of $13,358.40. Following the transaction, the director owned 325,059 shares of the company’s stock, valued at approximately $5,899,820.85. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Maplight Therapeutics Trading Down 2.2%

NASDAQ:MPLT opened at $17.63 on Thursday. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The firm has a market capitalization of $799.87 million and a P/E ratio of -0.47. The firm has a 50-day moving average of $17.79.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Jefferies Financial Group initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price target for the company. Stifel Nicolaus began coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price target for the company. Morgan Stanley assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price target on the stock. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Finally, Weiss Ratings assumed coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Maplight Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new position in shares of Maplight Therapeutics in the fourth quarter valued at approximately $49,154,000. Ghisallo Capital Management LLC acquired a new stake in Maplight Therapeutics during the 4th quarter worth approximately $351,000. Diadema Partners LP bought a new stake in Maplight Therapeutics in the 4th quarter valued at $1,120,000. Barclays PLC acquired a new position in Maplight Therapeutics in the 4th quarter valued at $464,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics during the 4th quarter worth $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.